Markus Follmann
5PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jun 11, 2025
Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy.Hartmut Beck, Stefanie Mesch, Stefanie Zimmermann
|Sep 05, 2023
Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders.Susanne Roehrig, Jens Ackerstaff, Eloísa Jiménez Núñez
|Apr 11, 2023
New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.Alexandros Vakalopoulos, Frank Wunder, Ingo V Hartung
|Dec 08, 2022
BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor.Daniel Meibom, Sina Micus, Anna Lena Andreevski
|May 31, 2017
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.Markus Follmann, Jens Ackerstaff, Gorden Redlich
Pageof 1
